Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Coagulation01:09

Coagulation

12.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
12.2K
Coagulation01:06

Coagulation

1.7K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.7K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association of estimated citrate load with frozen plasma versus four-factor prothrombin complex concentrate for coagulopathy after cardiac surgery: a <i>post hoc</i> exploratory analysis of the FARES-II randomised controlled trial.

BJA open·2026
Same author

Management of anticoagulation in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: guidance from the ISTH SSC on Perioperative and Critical Care Haemostasis and Thrombosis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Response to the comment by Gando on the updated definition and scoring of disseminated intravascular coagulation.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Development, validation, and user-centric evaluation of an interpretable machine learning decision support tool for the preoperative prediction of mild bleeding disorders (MBD-Check): a prospective diagnostic prediction study.

The Lancet. Digital health·2026
Same author

How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Designing biomarker-selected international trials in sepsis-associated coagulopathy.

Journal of thrombosis and haemostasis : JTH·2026

Related Experiment Video

Updated: Apr 11, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

121

Point of care and factor concentrate-based coagulation algorithms.

Oliver M Theusinger1, Philipp Stein1, Jerrold H Levy2

  • 1Institute of Anesthesiology, University and University Hospital of Zurich, Zurich, Switzerland.

Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie
|May 29, 2015
PubMed
Summary

Reducing blood product transfusions is crucial due to associated risks. Point-of-care (POC) devices and algorithms guide goal-directed therapy, improving patient outcomes and potentially saving costs.

Keywords:
BleedingCardiac surgeryGoal-directed transfusionsPOCPatient blood managementPoint of care devicesROTEM®ThrombelastometryTransfusion managementTrauma

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.6K

Related Experiment Videos

Last Updated: Apr 11, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

121
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.6K

Area of Science:

  • Transfusion Medicine
  • Point-of-Care Testing
  • Hemorrhage Management

Background:

  • Increasing evidence links blood transfusions to adverse events, including higher mortality and morbidity.
  • There is a growing need to minimize blood product exposure in clinical practice.
  • Current transfusion practices often lack objective monitoring, leading to potential overuse.

Purpose of the Study:

  • To highlight the importance of point-of-care (POC) devices integrated with algorithms for limiting blood product use.
  • To advocate for goal-directed transfusions and targeted factor concentrate administration.
  • To emphasize evidence-based strategies for managing bleeding patients and reducing transfusion-related risks.

Main Methods:

  • Utilizing point-of-care (POC) devices for real-time monitoring of coagulation status.
  • Implementing evidence-based algorithms to guide transfusion decisions and factor concentrate use.
  • Comparing outcomes and cost-effectiveness of algorithm-guided therapy versus empiric blood product administration.

Main Results:

  • POC-based algorithms enable goal-directed transfusions and precise factor concentrate application.
  • These strategies effectively manage bleeding in various surgical settings (e.g., cardiac, liver, trauma).
  • Factor concentrates offer potential cost savings and improved patient outcomes compared to traditional blood products.

Conclusions:

  • Empiric, uncontrolled use of blood products without POC monitoring is no longer supported by evidence.
  • POC devices and algorithms are essential for optimizing transfusion strategies and patient care.
  • Adopting factor concentrates and evidence-based algorithms aligns with WHO standards and improves patient safety and resource utilization.